vaccine development — grants

Sort

82,697 grants matching “vaccine development”

Development of IN-003PI as passive immunization against human metapneumovirus infection

$1,013,468

Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI

Systems Biology Approaches to Viral Pathogenesis and Immunity

$1,013,435

Michael G Katze · Oregon Health & Science University · U54 · FY2009 · AI

mRNA-based chimeric membrane protein vaccination strategies directed at the MPER

$1,013,381

Mikyung Kim · Dana-Farber Cancer Inst · P01 · FY2024 · AI

IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A

$1,013,003

Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI

University of Miami Pediatric Perinatal HIV/AIDS Clinical Trails Unit

$1,012,788

Gwendolyn B. Scott · University Of Miami School Of Medicine · U01 · FY2008 · AI

Human EGFRvIII-specific BiTE for the treatment of Glioblastoma

$1,012,736

John H Sampson · Duke University · U01 · FY2018 · NS

Influenza Immunity: Protective Mechanisms Against Pandemic Respiratory Virus

$1,012,718

Mark M Davis · Stanford University · U19 · FY2010 · AI

Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1

$1,012,608

Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2017 · AI

University of California, San Diego Clinical Trial Unit

$1,012,463

Stephen A Spector · University Of California, San Diego · UM1 · FY2012 · AI

Malaria Parasite Ligands And Host Cell Receptors

$1,012,433

Louis Miller · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI

Broad spectrum therapeutics targeting resolvase enzymes

$1,012,363

Frederic D Bushman · University Of Pennsylvania · U01 · FY2009 · AI

Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.

$1,012,212

B. Kim Lee Sim · Sanaria, Inc. · U01 · FY2025 · AI

Antigen recognition and activation of B-cell receptors of HIV-1 broadly neutralizing antibodies

$1,012,192

S Munir Alam · Duke University · R01 · FY2022 · AI

Development of strategies to achieve immunoprotection against Cryptosporidiosis

$1,012,009

Saul R Tzipori · University Of Maryland Baltimore · U19 · FY2016 · AI

A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States

$1,011,983

Pablo Tamayo · University Of California, San Diego · U01 · FY2017 · CA

HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals

$1,011,819

Peter B. Gilbert · Fred Hutchinson Cancer Research Center · UM1 · FY2022 · AI

Molecularly Targeted Vaccines for Anthrax

$1,011,633

Kemp Bailey Cease · University Of Michigan At Ann Arbor · U01 · FY2006 · AI

Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure

$1,011,413

Sharon Riddler · University Of Pittsburgh At Pittsburgh · U01 · FY2021 · AI

Impact of HIV on the human alveolar environment drivingthe early events of Mycobacterium tuberculosis infection

$1,011,348

Jordi B Torrelles · Texas Biomedical Research Institute · R01 · FY2024 · AI

PROGRESS: PRevention of cervical cancer using the Genotyping scREening and Same-day Self-sampling

$1,011,310

Youxiang Wang · Atila Biosystems, Inc. · R44 · FY2022 · CA

HIV pathogenesis, prevention and treatment in the Andes

$1,011,257

Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · U19 · FY2006 · AI

Development of IN-003PI as passive immunization against human metapneumovirus infection

Systems Biology Approaches to Viral Pathogenesis and Immunity

mRNA-based chimeric membrane protein vaccination strategies directed at the MPER

Modeling Inflammation in HIV Transmission

Protective and pathogenic B cell epitopes in Francisella tularensis

Induction of an Antitumor Immune Response in Patients with Melanoma

Project 2 - Novel Therapeutics for Emerging Alphavirus

IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A

University of Miami Pediatric Perinatal HIV/AIDS Clinical Trails Unit

Human EGFRvIII-specific BiTE for the treatment of Glioblastoma

Influenza Immunity: Protective Mechanisms Against Pandemic Respiratory Virus

Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1

University of California, San Diego Clinical Trial Unit

Malaria Parasite Ligands And Host Cell Receptors

Broad spectrum therapeutics targeting resolvase enzymes

Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.

Antigen recognition and activation of B-cell receptors of HIV-1 broadly neutralizing antibodies

Development of strategies to achieve immunoprotection against Cryptosporidiosis

A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States

HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals

Molecularly Targeted Vaccines for Anthrax

Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure

Impact of HIV on the human alveolar environment drivingthe early events of Mycobacterium tuberculosis infection

PROGRESS: PRevention of cervical cancer using the Genotyping scREening and Same-day Self-sampling

HIV pathogenesis, prevention and treatment in the Andes